

# The X-ray structures of HOBt-based immonium-type coupling reagents and the rearrangement of benzotriazolyl esters of $N_\alpha$ -protected amino acids or peptides: $N$ - vs. $O$ -substituted forms †

2 PERKIN

Peng Li and Jie Cheng Xu\*

Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Feng Lin Road, Shanghai 200032, P. R. China

Received (in Cambridge, UK) 16th May 2000, Accepted 20th October 2000


First published as an Advance Article on the web 5th December 2000

The crystal structures of HOBt-based immonium salts BOMI and BDMP are reported and show that these compounds crystallize as the  $N$ -substituted form rather than as the previously assigned  $O$ -substituted form. These unexpected phenomena are explained well by semiempirical PM3 calculations; the crystal structures of other HOBt-based onium salts can also be predicted by these theoretical calculations. The reaction mechanisms for coupling reactions mediated by these HOBt-based immonium salts and the rearrangement of the benzotriazolyl ester intermediate generated during the coupling reactions were studied by both experimental observations and theoretical calculations. The crystal structures of these benzotriazolyl esters were predicted by PM3 calculations and verified by reported X-ray data.

## Introduction


In previous studies, we have shown the high efficiency of the novel HOBt-derived immonium-type coupling reagents, BOMI, BDMP, BPMP and BMMP, in peptide synthesis.<sup>1,2</sup> They can be used to synthesize various oligopeptides and biologically active peptides in both solution and the solid phase with fast reaction speeds, negligible racemization and good yields.<sup>3,4</sup> In comparison to HOBt-based uronium- and phosphonium-type reagents, these immonium salts demonstrated much higher reactivities and lower racemization due to their unique structural features.<sup>4,5</sup> These immonium-type reagents were designed based upon the molecular structures of HOBt-based uronium-type coupling reagents, such as HBTU,<sup>6</sup> HBMDU,<sup>7</sup> and HBPYU,<sup>8</sup> by replacing one of the substituted amino groups in the uronium salts with hydrogen, alkyl or aryl. Such structural modifications cause the reaction-mediating carbons of these immonium salts to share relatively low electron density compared to the corresponding uronium salts, which results in their showing higher reactivities in nucleophilic reactions involved in peptide coupling.

Although these HOBt-based uronium- and immonium-type coupling reagents have been commonly used in peptide synthesis, the structures of these reagents have not been determined up to now, except for reagent HBTU. X-Ray analysis revealed that HBTU crystallizes as the unusual guanidinium  $N$ -oxide ( $N$ -form),<sup>9</sup> rather than the isomeric uronium form.<sup>6</sup> The




† Nomenclature and symbols of amino acids and peptides generally follow the recommendations of the IUPAC-IUB Joint Commission of Biochemical Nomenclature in: *Pure Appl. Chem.*, 1984, **56**, 595. The following additional abbreviations are used: Aib,  $\alpha$ -aminoisobutyric acid; BDMP, 5-(1*H*-benzotriazol-1-yl)-3,4-dihydro-1-methyl-2*H*-pyrrolidinium hexachloroantimonate  $N$ -oxide; BMMP, [(1*H*-benzotriazol-1-yloxy)methylmethylene]pyrrolidinium hexachloroantimonate; BOMI,  $N$ -(1*H*-benzotriazol-1-ylmethylene)- $N$ -methylmethanaminium hexachloroantimonate  $N$ -oxide; BPMP, [1-(1*H*-benzotriazol-1-yloxy)-phenylmethylene]pyrrolidinium hexachloroantimonate; HBMDU,  $O$ -(1*H*-benzotriazol-1-yl)- $N,N'$ -dimethyl- $N,N'$ -dimethyleneuronium hexafluorophosphate; HBPYU,  $O$ -(1*H*-benzotriazol-1-yl)- $N,N,N',N'$ -bis(tetramethylene)uronium hexafluorophosphate; HBTU,  $N$ -[(1*H*-benzotriazol-1-yl)(dimethylamino)methylene]- $N$ -methylmethanaminium hexafluorophosphate  $N$ -oxide; HOBt, 1-hydroxybenzotriazole.

structures of other HOBt-derived onium salts, for which X-ray data have not been obtained, have to be arbitrarily assigned as the  $O$ -form according to general chemical knowledge since



**Scheme 1** Synthesis of HOBt-derived immonium-type coupling reagents.



**Fig. 1** X-Ray crystal structures of HOBt-based immonium salts BOMI and BDMP.

there is no general rule that can predict whether these HOBt-based onium salts are present in the *O*-form or the *N*-form. To investigate the mechanism of coupling mediated by these reagents and to study the relationship between the reactivity and structures of these reagents, as well as develop more efficient peptide coupling reagents, resolving the true structures of these onium salts is necessary and significant. In this article, we try to solve these problems by both X-ray analysis and molecular orbital calculations. Since the benzotriazolyl esters of *N*<sub>α</sub>-protected amino acids or peptides, generated during peptide synthesis using HOBt-derived immonium salts, also present such a problem, the structures and tautomerization of these esters are also discussed herein.

## Results and discussion

### X-Ray structure determination of HOBt-derived immonium salts BOMI and BDMP ‡

These HOBt-based immonium salts were synthesized from the corresponding amides *via* three steps in high yields. For instance, reagents BOMI, BDMP, BPMP and BMMP can be prepared from *N,N*-dimethylformamide (DMF), *N*-methylpyrrolidone (NMP), *N*-benzoylpyrrolidine and *N*-acetylpyrrolidine, respectively, as shown in Scheme 1.

It was of great interest that determination of the solid state structures of the representative reagents of HOBt-derived immonium salts, BOMI and BDMP, by X-ray techniques showed that these compounds crystallized as the *N*-substituted form (Fig. 1), rather than as the previously assigned *O*-sub-

stituted form.<sup>1,2</sup> However, according to general chemical knowledge, these HOBt-derived immonium salts should be present in the *O*-form, hence the formation of these derivatives from the corresponding chloroimmonium salts was a typical nucleophilic substitution reaction, and the oxygen of the nucleophilic species benzotriazolyl oxy anion possessed higher electron density than the nitrogen in position 3, which resulted in the nucleophilic center being at the oxygen rather than the nitrogen.

A summary of the crystal structure determination of HOBt-based immonium salts BOMI and BDMP is presented in Table 1. C–H distances of these molecules fall in the range 0.904 to 1.094 Å for BOMI and 0.930 to 1.146 Å for BDMP. Sb–Cl distances fall in the range 2.339 to 2.391 Å for BOMI and 2.357 to 2.383 Å for BDMP, with a mean value of 2.363 Å for BOMI and 2.364 Å for BDMP. Some important bond lengths and torsion angles are listed in Table 2. Comparing BOMI and BDMP with *N*-oxide **16**, the exocyclic bonds from N3 and N1 are much shorter in BOMI (0.133 and 0.064 Å, respectively) and BDMP (0.121 and 0.067 Å, respectively), in keeping with a partial N3, C7 double-bond character due to the imine delocalization in BOMI and BDMP, with an accompanying electron shift from the *N*-oxide oxygen towards the triazole ring. Other bonds joining these units are also moderately adjusted in the two molecules. Among the two immonium salts, various bonds are of similar lengths except that the length of the reaction-mediating N3–C7 bond of BDMP is a little longer than that of BOMI; moreover, the intraannular C=N<sup>+</sup> double bond is to some extent constrained, reflected by the bond angles of BDMP. These geometric properties of BDMP may indirectly explain why BDMP demonstrates higher reactivity than BOMI in peptide synthesis.

‡ CCDC reference number 188/276. See <http://www.rsc.org/suppdata/p2/b0/b003930f/> for crystallographic files in .cif format.

**Table 1** Structure determination summary for BOMI 1 and BDMP 2

Compound	BOMI	BDMP
<i>Crystal data</i>		
Chemical formula	C <sub>9</sub> H <sub>11</sub> N <sub>4</sub> OCl <sub>6</sub> Sb	C <sub>11</sub> H <sub>13</sub> N <sub>4</sub> OCl <sub>6</sub> Sb
Formula weight	525.68	551.72
Crystal system	Triclinic	Monoclinic
Space group	<i>P</i> 1 (#2)	<i>P</i> 2 <sub>1</sub> / <i>n</i> (#14)
Lattice parameters		
<i>a</i> /Å	9.058(2)	9.570(3)
<i>b</i> /Å	15.729(4)	14.443(1)
<i>c</i> /Å	6.598(1)	14.261(2)
<i>α</i> /°	94.21(2)	
<i>β</i> /°	98.99(2)	98.99(2)
<i>γ</i> /°	73.38(2)	
<i>V</i> /Å <sup>3</sup>	889.4(4)	1907.6(6)
<i>Z</i>	2	4
<i>μ</i> (MoKα)/cm <sup>-1</sup>	24.50	22.89
<i>Data collection</i>		
Temperature/°C	20.0	20.0
Reflections collected	2943	3937
Independent reflections	2727 ( <i>R</i> <sub>int</sub> = 0.076)	3709 ( <i>R</i> <sub>int</sub> = 0.020)
Observed reflections	2247 [ <i>I</i> > 3.00σ ( <i>I</i> )]	2355 [ <i>I</i> > 2.50σ ( <i>I</i> )]

**Table 2** Selected bond lengths (Å), bond angles, and torsion angles (°) for compounds BOMI and BDMP

Bond lengths	Bond angles			Torsion angles					
	BOMI	BDMP	16 <sup>10</sup>	BOMI	BDMP	BOMI	BDMP		
O1–N1	1.251(7)	1.248(5)	1.315(2)	N3–C7–N4	127.7(7)	125.7(4)	N2–N3–C7–C4	11(1)	1.9(7)
N1–N2	1.309(8)	1.303(5)	1.315(2)	N4–C7–C8	—	112.7(4)	N1–N2–N3–C7	173.9(7)	–176.6(4)
N2–N3	1.375(8)	1.397(5)	1.341(2)	C7–N4–C10	—	111.9(4)	C1–C6–N3–N7	173.9(6)	176.6(4)
N3–C6	1.413(9)	1.406(5)	1.369(2)	C7–N4–C11	—	130.9(4)	N3–C7–N4–C11	—	3.2(8)
C6–C1	1.379(10)	1.363(6)	1.392(3)	C7–N4–C9	118.3(6)	—	N4–C7–N3–C6	–175.6(7)	–174.8(4)
C1–N1	1.423(10)	1.407(6)	1.369(2)	N4–C10–C9	—	105.4(4)	C6–N3–C7–C8	—	6.6(7)
N3–C7	1.348(9)	1.360(5)	1.481	C8–C9–C10	—	106.1(4)	O–N1–N2–N3	–177.7(6)	179.4(4)
C7–N4	1.289(10)	1.291(5)	—	C7–C8–C9	—	104.0(4)	N3–C6–C5–C4	–179.5(8)	179.1(5)

### Semiempirical PM3 calculations and the prediction of the structures of HOBt-based onium salts

In the X-ray studies of HOBt-based immonium-type coupling reagents, BOMI and BDMP, we found both of these compounds crystallized unexpectedly in the *N*-substituted form rather than the isomeric *O*-form. In order to explain this phenomenon and try to find a general rule that can predict the structures of these HOBt-based onium salts, molecular orbital calculations were carried out. With regard to the size and the structures of these compounds, we adopted semiempirical methods in this study, and only the carbocation moieties of these onium salts were calculated. The PF<sub>6</sub><sup>–</sup> or SbCl<sub>6</sub><sup>–</sup> counterions were not taken into account in order to simplify the calculation procedures. Since these anions do not participate in the rearrangement of the HOBt-based carbocations and both of the tautomers contain the same counterion, the relative stabilities and energies of these carbocation moieties reflect those of the whole molecules. In comparison to AM1 and MNDO, the PM3 semiempirical method can more accurately handle this kind of problem. The method was affirmed to be more reliable than AM1 by comparison with *ab initio* calculations.<sup>11</sup> Moreover, these HOBt-based onium salts are nitrogen-rich and oxygen-containing, therefore the PM3 method can give better results than the AM1 method.<sup>12,13</sup>

Consequently, the calculation results indicated that the *N*-substituted forms of reagents BOMI 1 and BDMP 2 were 10.5 and 14.5 kcal mol<sup>-1</sup>, respectively, more stable than the corresponding *O*-substituted tautomers using the PM3 method (Table 3). The *N*-form of the uronium/aminium salt HBTU 5 was also more stable than the corresponding *O*-form, which


was coincident with the X-ray structure of HBTU. In the case of other HOBt-based onium salts, PM3 calculations indicate that the *N*-oxides are more stable than the corresponding *O*-forms, and the relative energies ( $\Delta H_f$ ) are much higher than that of HBTU. Therefore, it is reasonable to predict that the HOBt-based onium salts BPMP, BMMP, HBMDU and HBPyU would crystallize as the *N*-oxides (*N*-form). We also tried using the AM1 semiempirical method to evaluate the relative stabilities of the *N*-forms and *O*-forms of these onium salts; the calculation results showed that the *O*-substituted forms were more stable (Table 3). These results obviously contradict the experimental observations, which was probably due to the AM1 method overestimating the instabilities of the *N*-oxides.

Although the above PM3 theoretical calculation results were consistent with experimental observations, these encouraging results should be treated with caution since they refer to gas-phase calculations. However, crystals of these reagents were obtained from solution and peptide coupling reactions mediated by these onium-type reagents were also carried out in the solution phase. Generally, The N<sup>+</sup>–O<sup>–</sup> functional group in the *N*<sup>3</sup>-substituted onium molecules can be strongly stabilized in a polar solvent. For example, in the polar solvent acetone, the relative permittivity of which is 20.56, the model compound, 3*H*-1,2,3-triazole *N*-oxide, was about 35 kcal mol<sup>-1</sup> more stable than in the gas phase according to *ab initio* calculations using Tomasi's SCRF procedure.<sup>11</sup> As for these much more complicated HOBt-derived uronium- and immonium-type molecules, the quantitative calculations including the solvation effect were beyond our limitations. But the general rules developed by model compound calculations indicated that the relative

**Table 3** Energies of HOBt-based immonium and uronium salts and their stabilities<sup>a</sup>

Compound <sup>b</sup>	Heat of formation $H_f$ /kcal mol <sup>-1</sup>	Total energy $U$ /au	Compound <sup>b</sup>	Heat of formation $H_f$ /kcal mol <sup>-1</sup>	Total energy $U$ /au	Relative energy <sup>c</sup> $\Delta H_f$ /kcal mol <sup>-1</sup>	Relatively stable tautomer	X-Ray structure
<b>1A<sup>+</sup></b> ( <i>N</i> -form)	250.9	-79.655	<b>1A<sup>+</sup></b> ( <i>O</i> -form)	261.4	-79.638	-10.5	<i>N</i> -form	<i>N</i> -form
(AM1 method)	(312.6)	(-89.617)	(AM1 method)	(297.2)	(-89.642)	(15.4)	( <i>O</i> -form)	
<b>2A<sup>+</sup></b> ( <i>N</i> -form)	240.2	-89.519	<b>2A<sup>+</sup></b> ( <i>O</i> -form)	254.7	-89.496	-14.5	<i>N</i> -form	<i>N</i> -form
(AM1 method)	(296.0)	(-100.072)	(AM1 method)	(291.3)	(-100.079)	(4.7)	( <i>O</i> -form)	
<b>3A<sup>+</sup></b> ( <i>N</i> -form)	267.3	-117.889	<b>3A<sup>+</sup></b> ( <i>O</i> -form)	278.0	-117.872	-10.7	<i>N</i> -form	Unknown
<b>4A<sup>+</sup></b> ( <i>N</i> -form)	235.4	-95.013	<b>4A<sup>+</sup></b> ( <i>O</i> -form)	244.4	-94.999	-9.0	<i>N</i> -form	Unknown
<b>5A<sup>+</sup></b> ( <i>N</i> -form)	252.6	-97.162	<b>5A<sup>+</sup></b> ( <i>O</i> -form)	256.6	-97.155	-4.0	<i>N</i> -form	<i>N</i> -form
(AM1 method)	(353.0)	(-109.105)	(AM1 method)	(301.1)	(-109.187)	(51.9)	( <i>O</i> -form)	
<b>6A<sup>+</sup></b> ( <i>N</i> -form)	248.8	-96.041	<b>6A<sup>+</sup></b> ( <i>O</i> -form)	257.1	-96.027	-8.3	<i>N</i> -form	Unknown
<b>7A<sup>+</sup></b> ( <i>N</i> -form)	236.9	-116.880	<b>7A<sup>+</sup></b> ( <i>O</i> -form)	247.8	-116.863	-10.9	<i>N</i> -form	Unknown

<sup>a</sup> Calculated by PM3 semiempirical method. <sup>b</sup> A<sup>+</sup> refer to the carbocation moieties of these HOBt-based onium salts. <sup>c</sup> Relative stabilities ( $\Delta H_f$ ) =  $H_f$  (*N*-form) -  $H_f$  (*O*-form).


**Fig. 2** Proposed mechanism of coupling reactions mediated by the HOBt-based immonium type reagents.

energies of the *N*-substituted and *O*-substituted forms of immonium- and uronium-type reagents would increase in solution due to the solvation effect, compared to the gas phase. That means the *N*-substituted forms of onium salts would be even more stable than the corresponding *O*-substituted forms in solution.

#### The mechanism of HOBt-based immonium salt mediated coupling reactions and the rearrangement of benzotriazolyl esters of *N*<sub>α</sub>-protected amino acids and peptides

To study the influence of the isomerization of the HOBt-based immonium salts and their analogues on the coupling reaction

involved in peptide synthesis, the mechanism of peptide coupling reactions mediated by these immonium-type reagents was investigated. Under basic reaction conditions, the carboxylate anion initially attacks the  $\alpha$ -carbon atom of the immonium salt to form an unstable acyloxyimmonium intermediate with the release of benzotriazolyl oxy anion (BtO<sup>-</sup>). Then, the BtO<sup>-</sup> nucleophile attacks the acyloxyimmonium intermediate *via* two pathways to afford the corresponding benzotriazolyl ester and a small amount of *N*<sup>3</sup>-acylbenzotriazole 1-oxide intermediate. The benzotriazolyl ester intermediate can spontaneously rearrange into the corresponding *N*-acylated isomer. If an amino component was added into the reaction system, the two forms of the active intermediates



**Table 4** The UV and IR spectra of the benzotriazolyl esters Z-Gly-Phe-OBt 8 and Fmoc-MeVal-OBt 9

Compound	UV				IR			
	CH <sub>3</sub> CN		CHCl <sub>3</sub>		CH <sub>3</sub> CN		CHCl <sub>3</sub>	
	$\lambda_{\max}/\text{nm}$	<i>A</i> <sup>a</sup>	$\lambda_{\max}/\text{nm}$	<i>A</i> <sup>a</sup>	$\nu_{(\text{C-O})}/\text{cm}^{-1}$		$\nu_{(\text{C-O})}/\text{cm}^{-1}$	
8	282	<i>O</i> -form	1.238	286	6.455	1821 (m)	<i>O</i> -form	1818 (m)
	328	<i>N</i> -form	1.000	328	1.000	1729 (vs)	<i>N</i> -form (partly overlapped)	1732 (vs)
9	342	<i>N</i> -form	0.960	342	0.876	1685 (m)		1689 (vs)
	288	<i>O</i> -form	3.184	289	3.616	1826 (m)	<i>O</i> -form	1817 (m)
	328	<i>N</i> -form	1.000	328	1.000	1708 (vs)	<i>N</i> -form (overlapped)	1702 (vs)
	342	<i>N</i> -form	0.984	344	0.973			

<sup>a</sup> Related values based upon the characteristic absorption of *N*-oxide at 328 nm.

would react with the amine to give the corresponding amide. Otherwise, the intermediates can be isolated as the final products (Fig. 2).


The arrangement of the benzotriazolyl ester was further studied by UV, IR, <sup>1</sup>H NMR, and HPLC monitoring. For instance, in the synthesis of hindered peptide Fmoc-MeVal-Sar-OBzl by treating Fmoc-MeVal-OH and Sar-OBzl·HCl with reagent BDMP in the presence of 2,6-lutidine at -10 °C, the active intermediate Fmoc-MeVal-OBt was observed and isolated besides the dipeptide. TLC monitoring of the reaction mixture showed that the less polar *O*-acylated form of Fmoc-MeVal-OBt was first formed, which further rearranged into the more polar *N*-acylated form. When the *O*-form isomer was separated by preparative thin layer chromatography, the obtained product spontaneously rearranged into two forms again during storage. A similar phenomenon was also observed during the preparation of the HOBt-derived ester Z-Gly-Phe-OBt.

The UV spectra of Z-Gly-Phe-OBt indicated that this compound did exist, to some extent, in the *N*-acylated form, as revealed by the characteristic absorptions of *N*-oxide at 328 and 342 nm, besides existing as the *O*-isomer, characterized by the absorption at 1805–1825 cm<sup>-1</sup> in IR spectra. Moreover, the proportion of the *N*-substituted form in CH<sub>3</sub>CN was higher than in CHCl<sub>3</sub> since the more polar CH<sub>3</sub>CN can better stabilize the *N*-oxide isomer due to the solvation effect (Table 4). The <sup>1</sup>H NMR spectra of Z-Gly-Phe-OBt in CDCl<sub>3</sub> also demonstrated the existence of the two forms; however, only the *N*-acylated

form of the compound was observed in the more polar solvent acetone-d<sub>6</sub> which can strongly stabilize the *N*-oxide, and the spectrum becomes much simplified. In the case of compound Fmoc-MeVal-OBt, similar UV, IR, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectral features were also observed, but the extent and speed of the rearrangement were smaller and slower than those of Z-Gly-Phe-OBt as shown in Table 4.

#### Molecular orbital calculations and the prediction of the structures of benzotriazolyl esters

To explain and study the above rearrangement reactions of the benzotriazolyl esters of *N*<sub>α</sub>-protected amino acids and peptides, we calculated the relative stabilities of the *N*-form and the *O*-form of these benzotriazolyl esters. Semiempirical PM3 calculations revealed that the *N*-oxide of compound 8 was more stable than the corresponding *O*-acylated form by 3.74 kcal mol<sup>-1</sup> (Table 5). Therefore, we can infer that the *O*-form benzotriazolyl ester intermediate of immonium salt mediated coupling is kinetically preferred, which was proved by the TLC monitoring of the activation reactions using HOBt-derived immonium-type coupling reagents. When the reactions were carried out at low temperature (-10 °C), TLC, UV and IR analysis indicated that the *O*-form benzotriazolyl ester of the carboxylic component was initially generated and reacted immediately with the amino component to give the desired peptide. If the amino component was sterically hindered or was not added at all, the benzotriazolyl ester intermediate gradually



**Table 5** Energies of substituted benzotriazoles and their stabilities<sup>a</sup>

Compound	Heat of formation $H_f$ /kcal mol <sup>-1</sup>	Total energy $U$ /au	Compound	Heat of formation $H_f$ /kcal mol <sup>-1</sup>	Total energy $U$ /au	Relative energy <sup>b</sup> $\Delta H_f$ /kcal mol <sup>-1</sup>	Relatively stable tautomer	X-Ray structure
<b>8</b> (N-form)	-14.36	-205.483	<b>8</b> (O-form)	-10.62	-205.477	-3.74	N-form	Unknown
<b>9</b> (N-form)	22.68	-199.134	<b>9</b> (O-form)	21.21	-199.136	1.47	O-form	Unknown
<b>10</b> (N-form)	-6.51	-155.433	<b>10</b> (N-form)	-4.27	-155.429	-2.24	N-form	Unknown
<b>11</b> (N-form)	69.64	-97.779	<b>11</b> (O-form)	76.04	-97.769	-6.40	N-form	N-form <sup>10</sup>
<b>12</b> (N-form)	47.48	-127.109	<b>12</b> (O-form)	50.56	-127.104	-3.08	N-form	N-form <sup>14</sup>
<b>13</b> (N-form)	14.25	-91.390	<b>13</b> (N-form)	13.63	-91.391	0.62	O-form	O-form <sup>14</sup>
<b>14</b> (N-form)	35.18	-117.282	<b>14</b> (O-form)	36.14	-117.281	-0.96	N-form	N-form <sup>14</sup>
<b>15</b> (N-form)	-10.53	-105.402	<b>15</b> (O-form)	-8.02	-105.398	-2.51	N-form	N-form <sup>14</sup>
<b>16</b> (N-form)	-17.01	-99.926	<b>16</b> (O-form)	-9.34	-99.913	-7.67	N-form	N-form <sup>10</sup>

<sup>a</sup> Calculated by PM3 semiempirical method. <sup>b</sup> Relative stabilities ( $\Delta H_f$ ) =  $H_f$  (N-form) -  $H_f$  (O-form).

rearranged into the thermodynamically stable *N*-oxide at room temperature, which can be monitored by UV. As for the sterically hindered Fmoc-MeVal-OBt, PM3 calculations showed that the *N*-acylated form was 1.47 kcal mol<sup>-1</sup> less stable than the corresponding *O*-form. On the other hand, these theoretical results referred to the calculations *in vacuo* and the solvation effect was not taken into account while the experimental observations shown in Table 4 reflect the equilibria in solution. The N<sup>+</sup>-O<sup>-</sup> polar moieties of the *N*-form molecules could be further stabilized in solution, especially in a polar solvent; therefore, the *N*-form of compound **9** also exists in solution. Generally, the *N*-acylated forms of benzotriazolyl esters of *N*<sub>α</sub>-protected amino acids and peptides, such as **8**, **9** and **10**, were thermodynamically stable in solution as shown by both calculation results and the solvation effect, as well as proved by experimental observations.

We investigated the possibility of theoretical calculations using the semiempirical PM3 method predicting the crystal structures of benzotriazolyl esters. The benzotriazolyl esters **11–15** and acid **16** for which X-ray structures have been reported were selected as candidates, so that we could evaluate the accuracy of the calculation results. Encouragingly, all the calculation results were coincident with the experimental observations as shown in Table 5. Therefore, a useful way to predict the X-ray structures of these kind of compounds would be by PM3 calculations. It is worth pointing out that the above calculation results should be treated with caution since they just reflect the relative stabilities *in vacuo*; the crystal packing contributions were not taken into account.

## Conclusions

X-Ray analysis revealed that HOBt-derived immonium-type peptide coupling reagents BOMI and BDMP crystallize as *N*-oxides, rather than the previously assigned *O*-substituted forms. Semiempirical PM3 calculations indicated that the *N*-forms of HOBt-based onium salts were more stable than the corresponding isomeric *O*-forms *in vacuo*. Other HOBt-derived onium salts, such as BPMP, BMMP, HBMDU and HBPyU,

for which X-ray data have not been obtained, are proposed to crystallize as *N*-oxides as suggested by the PM3 calculation results. The reaction mechanism for coupling reactions mediated by these HOBt-derived immonium salts was investigated. The rearrangement of the benzotriazolyl ester intermediate generated during the coupling reaction was observed and studied by both experimental observations and theoretical calculations. TLC, UV, and IR monitoring of model coupling reactions showed that the key reaction mediators, benzotriazolyl esters of the carboxylic components, were initially generated as the *O*-acylated forms, then spontaneously rearranged into the corresponding *N*-substituted forms, a finding which could be explained well by PM3 calculations. The crystal structures of these benzotriazolyl esters can be predicted well by the semiempirical PM3 calculations. But the above calculation results should be treated with caution since they just reflect the relative stabilities *in vacuo*; the solvation effects and the crystal packing contributions were not considered.

## Experimental

### General

Melting points were taken on a digital melting point apparatus and are uncorrected. Infrared spectra were recorded on a Shimadzu IR-440 spectrometer. Mass spectra were recorded on HP 5989A and VG QUATTRO mass spectrometers. <sup>1</sup>H NMR spectra were recorded on Bruker AM 300 (300 MHz) and Bruker DRX-400 (400 MHz) instruments using TMS as the internal standard. Combustion analysis for elemental composition was carried out on an Italy MOD 1106 analyzer. Optical rotations were determined using a Perkin-Elmer 241 MC polarimeter. Flash column chromatography was performed with 300–400 mesh silica gel, and analytical thin layer chromatography was performed on precoated silica gel plates (60F-254) with the systems (v/v) indicated. Solvents and reagents were purified by standard methods as necessary. Amino acids were L-configuration if not otherwise stated. HOBt, SbCl<sub>5</sub> and DCC were purchased from Aldrich Chemical Co. (Milwaukee, WI), and used without purification. Fmoc-*N*-Methylvaline was

synthesized by the procedure of Freidinger *et al.*<sup>15</sup> The synthesis and spectral properties of compounds BOMI<sup>3</sup> and BDMP<sup>4</sup> have been described previously.

### Synthesis of compounds

**[1-(1*H*-Benzotriazol-1-yloxy)phenylmethylene]pyrrolidinium hexachloroantimonate (BPMP, 3).** A solution of *N*-benzoylpyrrolidine (7.01 g, 40 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was added dropwise to a solution of bis(trichloromethyl) carbonate (3.96 g, 13.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at 0 °C under nitrogen atmosphere. After being stirred for approximately 1.5 h, when the evolution of carbon dioxide had ceased, a 0.89 M solution of SbCl<sub>5</sub> in CHCl<sub>3</sub> (41.0 mL) was added dropwise at -30 °C under vigorous stirring. The reaction mixture was stirred at 0 °C for 2 h, the resultant suspension was filtered under nitrogen atmosphere, washed with cold CH<sub>2</sub>Cl<sub>2</sub> and dried *in vacuo*. Recrystallization from CH<sub>3</sub>CN-CHCl<sub>3</sub> gave [(chloro)phenylmethylene]pyrrolidinium hexachloroantimonate (15.9 g, yield 82.6%). This intermediate (2.647 g, 5.0 mmol) was dissolved in dry CH<sub>3</sub>CN, then the potassium salt of HOBT (0.865 g, 5.0 mmol) was added at -30 °C with stirring under argon atmosphere. After the reaction mixture had been stirred at room temperature for 2 h, it was filtered and the filtrate was concentrated under reduced pressure, then the residue was recrystallized from CH<sub>3</sub>CN-Et<sub>2</sub>O at low temperature to give 2.86 g product as a crystalline solid, yield 91.1%, mp 93–94 °C (dec.). IR (KBr)  $\nu$  3100w, 1616vs, 1494s, 1467s, 1417m, 1331s, 1151m, 1065m, 752s, 705m, 638w cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, acetone-d<sub>6</sub>)  $\delta$  1.95 (m, 4H, 2 $\beta$ -CH<sub>2</sub>), 3.57 (m, 4H, 2 $\alpha$ -CH<sub>2</sub>), 7.34–7.97 (m, 9H, aryl); <sup>13</sup>C NMR (300 MHz, acetone-d<sub>6</sub>)  $\delta$  25.0 (1C,  $\beta$ -CH<sub>2</sub>), 26.6 (1C,  $\beta$ -CH<sub>2</sub>), 48.4 (1C,  $\alpha$ -CH<sub>2</sub>), 51.2 (1C,  $\alpha$ -CH<sub>2</sub>), 111.3 (1C, 4-CH-OBt), 118.4 (1C, 7-CH-OBt), 127.6 (1C, 5-CH-OBt), 128.2 (2C, 3',5'-CH-Ph), 129.0 (1C, 6-CH-OBt), 129.4 (1C, 7b-C-OBt), 129.5 (2C, 2',6'-CH-Ph), 132.0 (1C, 4'-CH-Ph), 134.4 (1C, 1'-C-Ph), 141.3 (1C, 7a-C-OBt), 170.8 (1C, C=N<sup>+</sup>). Anal. Calcd. for C<sub>17</sub>H<sub>17</sub>Cl<sub>6</sub>N<sub>4</sub>OSb: C, 32.52; H, 2.71; N, 8.92%. Found: C, 32.23; H, 2.61; N, 8.84%.

**[1*H*-Benzotriazol-1-yloxy)methylmethylene]pyrrolidinium hexachloroantimonate (BMMP, 4).** The synthetic procedure was similar to that of BPMP. Mp 110–112 °C (dec.). IR (KBr)  $\nu$  3122w, 2955w, 1641s, 1624s, 1493s, 1471m, 1449s, 1335m, 1057w, 766m, 743sh cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, acetone-d<sub>6</sub>)  $\delta$  2.03 (m, 4H, 2 $\beta$ -CH<sub>2</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 3.62 (m, 2H,  $\alpha$ -CH<sub>2</sub>), 3.78 (m, 2H,  $\alpha$ -CH<sub>2</sub>), 7.49 (m, 1H, 5-CH-OBt), 7.60 (m, 1H, 6-CH-OBt), 7.76 (d,  $J$  = 8.4 Hz, 1H, 4-CH-OBt), 7.97 (d,  $J$  = 8.6 Hz, 1H, 7-CH-OBt); <sup>13</sup>C NMR (300 MHz, acetone-d<sub>6</sub>)  $\delta$  19.9 (1C, CH<sub>3</sub>), 25.1 (1C,  $\beta$ -CH<sub>2</sub>), 25.9 (1C,  $\beta$ -CH<sub>2</sub>), 48.8 (1C,  $\alpha$ -CH<sub>2</sub>), 50.1 (1C,  $\alpha$ -CH<sub>2</sub>), 110.7 (1C, 4-CH-OBt), 119.3 (1C, 7-CH-OBt), 126.2 (1C, 5-CH-OBt), 128.4 (1C, 6-CH-OBt), 129.3 (1C, 7b-C-OBt), 143.0 (1C, 7a-C-OBt), 152.5 (1C, C=N<sup>+</sup>). Anal. Calcd. for C<sub>12</sub>H<sub>15</sub>Cl<sub>6</sub>N<sub>4</sub>OSb: C, 25.48; H, 2.67; N, 9.90%. Found: C, 25.33; H, 2.49; N, 9.85%.

***N*-(Benzyloxycarbonyl)glycylphenylalanine 1*H*-benzotriazolyl ester (Z-Gly-Phe-OBt, 8).** To a solution of Z-Gly-Phe-OH (0.713 g, 2 mmol) and HOBT (0.270 g, 2 mmol) in THF (6 mL), DCC (0.413 g, 2 mmol) was added at room temperature. After the reaction mixture was stirred for 1 h, it was cooled to -30 °C for 2 h to make DCU precipitate completely. The cold mixture was filtered, the filtrate was concentrated and dried *in vacuo*. Recrystallization from THF-AcOEt-Pe gave 0.766 g pure product as a colorless crystalline solid. Yield 80.9%, mp 124–125 °C,  $[\alpha]_D^{25}$  -8.2 (*c* 1, CHCl<sub>3</sub>). IR (KBr)  $\nu$  3305s, 3065w, 1808s, 1722s, 1660s, 1544s, 1242m, 1092w, 746m cm<sup>-1</sup>; UV (CHCl<sub>3</sub>)  $\lambda_{\max}$  256, 286, 328, 342 nm; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) signals assigned by COSY  $\delta$  7.05–8.38 (m, 14H, aryl), 6.95, 6.76 (2d,  $J$  = 7 Hz, 1H, NH-Phe), 5.74, 4.83 (2m, 1H,  $\alpha$ -CH-Phe), 5.56, 5.61 (2 br, 1H, NH-Gly), 5.08–5.20

(m, 2H, CH<sub>2</sub>-Z), 3.76–4.09 (m, 2H,  $\alpha$ -CH<sub>2</sub>-Gly), 3.18, 3.39 (2m, 2H,  $\beta$ -CH<sub>2</sub>-Phe); <sup>1</sup>H NMR (400 MHz, acetone-d<sub>6</sub>)  $\delta$  7.94 (d,  $J$  = 8.4 Hz, 1H, 7-CH-OBt), 7.71 (d,  $J$  = 8.4 Hz, 1H, 4-CH-OBt), 7.55 (t,  $J$  = 8.1 Hz, 1H, 6-CH-OBt), 7.43 (t,  $J$  = 8.1 Hz, 1H, 5-CH-OBt), 7.15–7.40 (m, 10H, Ph-Z, Ph-Phe), 5.10 (s, 2H, CH<sub>2</sub>-Z), 4.74 (dd,  $J$  = 7.3 Hz,  $J'$  = 5.4 Hz, 1H,  $\alpha$ -CH-Phe), 3.83 (m, 2H,  $\alpha$ -CH<sub>2</sub>-Gly), 3.18, 3.04 (2dd,  $J$  = 13.9 Hz,  $J'$  = 5.4 Hz, 2H,  $\beta$ -CH<sub>2</sub>-Phe); <sup>13</sup>C NMR (400 MHz, acetone-d<sub>6</sub>) signals assigned by HMQC  $\delta$  38.1 (1C,  $\beta$ -CH<sub>2</sub>-Phe), 44.7 (1C,  $\alpha$ -CH<sub>2</sub>-Gly), 54.1 (1C,  $\alpha$ -CH-Phe), 67.0 (1C, CH<sub>2</sub>-Z), 110.3 (1C, 4-CH-OBt), 119.9 (1C, 7-CH-OBt), 125.4 (1C, 5-CH-OBt), 128.1 (1C, 6-CH-OBt), 127.5, 128.7, 129.1, 129.2, 130.2 (12C, Ph-Phe, 5CH-Ph-Z, 7b-C-OBt), 137.9 (1C, 1'-C-Ph-Z), 138.1 (1C, 7a-C-OBt), 157.5 (1C, CO-Z), 170.0 (1C, CO-Phe), 172.8 (1C, CO-Gly); FABMS  $m/z$  474 [M + H]<sup>+</sup>, 339 [M - OBt]<sup>+</sup>, 91 [PhCH<sub>2</sub>]<sup>+</sup>. Anal. Calcd. for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>5</sub>·0.25H<sub>2</sub>O: C 62.82, H 4.96, N 14.65%. Found: C 62.79, H 4.80, N 14.54%.

***N*-[(9*H*-Fluoren-9-ylmethoxy)carbonyl]-*N*-methylvaline benzotriazolyl ester (Fmoc-MeVal-OBt, 9).** 2,6-Lutidine (0.37 mL, 3.2 mmol) was added to a cold mixture (-10 °C) of Fmoc-MeVal-OH (353 mg, 1.0 mmol), Sar-OBzl·HCl (237 mg, 1.1 mmol), and BDMP (607 mg, 1.1 mmol) in THF (5 mL), then stirred for 1 min cold and 3 h at room temperature. The reaction mixture was directly purified by flash chromatography on a silica gel column eluted with AcOEt-petroleum ether (Pe) (1:4) to give, besides the dipeptide Fmoc-MeVal-Sar-OBzl, Fmoc-MeVal-OBt. Yield: 243 mg (51.6%), mp 43–44 °C,  $[\alpha]_D^{25}$  -69.2° (*c* 0.5, CHCl<sub>3</sub>),  $R_{11}$  0.67 (*O*-form, AcOEt-Pe: 1:2),  $R_{12}$  0.40 (*N*-form, AcOEt-Pe: 1:2). IR (KBr)  $\nu$  3067w, 2966w, 1818m, 1702vs, 1464m, 1451sh, 1169m, 740s cm<sup>-1</sup>; UV (CH<sub>2</sub>Cl<sub>2</sub>)  $\lambda_{\max}$  262, 289, 329, 344 nm; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) two conformers and two isomers  $\delta$  0.70, 0.85, 1.01, 1.23 (4d,  $J$  = 6.4 Hz, 6H, 2 $\gamma$ -CH<sub>3</sub>-Val), 2.16, 2.41 (2m, 1H,  $\beta$ -CH-Val), 2.92, 2.98, 3.02, 3.04 (4s, 3H, *N*-CH<sub>3</sub>), 4.08–4.85 (m, 4H, CH<sub>2</sub>-Fmoc, 9-CH-fluorenyl,  $\alpha$ -CH-Val), 7.08–8.12 (m, 2H, aryl); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) two conformers and two isomers  $\delta$  18.4, 18.9, 19.1, 19.4, 19.5, 19.6, 19.7, 19.8, 27.4, 27.7, 28.3, 28.7, 30.0, 30.4, 31.5, 32.1, 46.9, 47.3, 62.3, 63.2, 64.0, 65.9, 67.6, 67.7, 68.0, 68.1, 108.1, 108.5, 112.8, 114.4, 119.9, 120.0, 120.5, 120.9, 124.5, 124.9, 125.5, 127.0, 127.1, 127.2, 127.6, 128.0, 128.8, 129.2, 129.7, 131.0, 141.4, 141.6, 143.3, 143.4, 143.8, 144.0, 144.1, 144.5, 156.2, 156.3, 156.9, 157.4, 167.4, 167.5, 173.8, 174.4. Anal. Calcd. for C<sub>27</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>·0.25H<sub>2</sub>O: C, 68.27; H, 5.62; N, 11.79%. Found: C, 68.39; H, 5.57; N, 11.62%.

### Crystal structure determination and refinement

Single crystals of **1** and **2** were obtained from acetone-ether under argon atmosphere. Crystal data and the conditions of data collection are summarized in Table 1. The structure of BOMI was solved by heavy-atom Patterson methods<sup>16</sup> and expanded using Fourier techniques;<sup>17</sup> the structure of BDMP was solved by direct methods with the SHELXS 86 software package,<sup>18</sup> and expanded using Fourier techniques. Neutral atom scattering factors were taken from Cromer and Waber.<sup>19</sup> The values for the mass attenuation coefficients are those of Creagh and Hubbell.<sup>20</sup> All calculations were performed using the teXsan<sup>21</sup> crystallographic software package of Molecular Structure Corporation.<sup>21</sup>

### Calculations

Semiempirical molecular orbital calculations were carried out using Hyperchem for Windows from Hypercube with PM3 or AM1 parametrizations. Geometry optimizations were first performed using standard methods of molecular dynamics with a force field MM+, then further performed by AM1 or PM3 calculations with the Polak-Ribiere conjugate gradient method. Several starting geometries were used for the geometry

optimizations to ensure the optimized structures correspond to global minima.

## Acknowledgements

We thank the National Natural Science Foundation for the support of this work.

## References

- 1 P. Li and J. C. Xu, *Tetrahedron Lett.*, 1999, **50**, 3605.
- 2 P. Li and J. C. Xu, *Chem. Lett.*, 1999, 1163.
- 3 P. Li and J. C. Xu, *J. Pept. Res.*, 2000, **55**, 110.
- 4 P. Li and J. C. Xu, *Chin. J. Chem.*, 2000, **18**, 85.
- 5 P. Li and J. C. Xu, *J. Org. Chem.*, 2000, **65**, 2951.
- 6 V. Dourtoglou, J. C. Ziegler and B. Gross, *Tetrahedron Lett.*, 1978, 1269.
- 7 Y. Kiso, Y. Fujiwara, T. Kimura, A. Nishitani and K. Akaji, *Int. J. Pept. Protein Res.*, 1992, **40**, 308.
- 8 S. Q. Chen and J. C. Xu, *Tetrahedron Lett.*, 1992, **33**, 647.
- 9 I. Abdelmoty, F. Albericio, L. A. Carpino, B. M. Foxman and S. A. Kates, *Lett. Pept. Sci.*, 1994, **1**, 57.
- 10 S. Vagarajan, S. R. Wilson and K. L. Rinehart, Jr., *J. Org. Chem.*, 1985, **50**, 2174.
- 11 E. Anders, A. R. Katritzky, N. Malhotra and J. Stevens, *J. Org. Chem.*, 1992, **57**, 3698.
- 12 R. Karaman, J. T. L. Huang and J. L. Fry, *J. Comput. Chem.*, 1990, **11**, 1009.
- 13 S. Uchiyama, T. Santa and K. Imai, *J. Chem. Soc., Perkin Trans. 2*, 1999, 569.
- 14 J. Singh, R. Fox, M. Wong, T. P. Kissick and J. L. Moniot, *J. Org. Chem.*, 1988, **53**, 205.
- 15 R. M. Freidinger, J. S. Hinkle, D. S. Perlow and B. H. Arison, *J. Org. Chem.*, 1983, **48**, 77.
- 16 PATTY: P. T. Beurskens, G. Admiraal, G. Beurskens, W. P. Bosman, S. Garcia-Granda, R. O. Gould, J. M. M. Smits and C. Smykalla (1992). The DIRDIF program system, Technical Report of the Crystallography Laboratory, University of Nijmegen, Netherlands.
- 17 DIRDIF92: P. T. Beurskens, G. Admiraal, G. Beurskens, W. P. Bosman, S. Garcia-Granda, R. O. Gould, J. M. M. Smits and C. Smykalla (1992). The DIRDIF program system, Technical Report of the Crystallography Laboratory, University of Nijmegen, Netherlands.
- 18 G. M. Sheldrick, *Crystallographic Computing 3*, G. M. Sheldrick, C. Kruger and R. Goddard, Eds., Clarendon Press, Oxford, UK, 1985, p. 175.
- 19 D. T. Cromer and J. T. Waber, *International Tables for X-ray Crystallography*, Vol. IV, the Kynoch Press, Birmingham, England, 1974, Table 2.2 A.
- 20 D. C. Creagh and J. H. Hubbell, *International Tables for Crystallography*, Vol. C, Kluwer Academic Publishers, Boston, 1992, Table 4.2.4.3, p. 200.
- 21 *teXsan: Crystal Structure Analysis Package*, Molecular Structure Corporation, 1992.